bluebird bio vs CRISPR Therapeutics Which Should You Buy?

Bluebird bio and CRISPR Therapeutics are two prominent companies in the biotechnology sector, both focused on developing cutting-edge treatments using gene editing technology. Bluebird bio has made a name for itself with its innovative gene therapy treatments, while CRISPR Therapeutics is known for its pioneering work in CRISPR-Cas9 technology. Investors have been closely watching the stock performance of both companies, as they continue to make strides in the field of genetic medicine. Let's compare and analyze the potential of Bluebird bio vs CRISPR Therapeutics stocks.

bluebird bio or CRISPR Therapeutics?

When comparing bluebird bio and CRISPR Therapeutics, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between bluebird bio and CRISPR Therapeutics.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. bluebird bio has a dividend yield of -%, while CRISPR Therapeutics has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. bluebird bio reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, CRISPR Therapeutics reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with bluebird bio P/E ratio at -0.25 and CRISPR Therapeutics's P/E ratio at -19.52. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. bluebird bio P/B ratio is 1.48 while CRISPR Therapeutics's P/B ratio is 2.41.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, bluebird bio has seen a 5-year revenue growth of -0.74%, while CRISPR Therapeutics's is 70.70%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with bluebird bio's ROE at -207.25% and CRISPR Therapeutics's ROE at -12.15%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $0.40 for bluebird bio and $53.00 for CRISPR Therapeutics. Over the past year, bluebird bio's prices ranged from $0.34 to $5.53, with a yearly change of 1526.47%. CRISPR Therapeutics's prices fluctuated between $43.42 and $91.10, with a yearly change of 109.81%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.